寻求最佳的重复液体生物标志物评估,以提高临床试验的精度和统计能力:SLIM方法
Hiroko H Dodge1, Liu Chen1, Chao-Yi Wu1
1Department of Neurology, Interdisciplinary Brain Center, Massachusetts General Brigham, Harvard Medical School, Charlestown, Massachusetts, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|October 22, 2025
概括
创新的单臂带入多项措施 (SLIM) 设计使用重复的血生物标志物评估来减少早期阿尔茨海默病和相关痴呆症试验中的样本大小. 与传统设计相比,这种方法提高了精度,并降低了招聘负担.
科学领域:
- 生物标志物研究的研究.
- 临床试验的设计
- 神经科学是一个神经科学.
背景情况:
- 血生物标志物是阿尔茨海默病和相关痴呆症 (ADRD) 试验中的关键代用结果.
- 单臂安慰剂引入设计通过将受试者之间的变化降到最低,提供了具有成本效益的替代方案.
- 血生物标志物的个体内变异性可以掩盖治疗效果.
研究的目的:
- 引入创新的早期临床试验设计,单臂带入多种措施 (SLIM).
- 为了应对血生物标志物的个体内变异性的挑战.
- 为了减少ADRD试验中的样本大小要求和招聘负担.
主要方法:
- 在SLIM设计中,在治疗前期和治疗后期都进行了反复的生物标志物评估.
- 使用模拟研究来评估设计的有效性.
- 专注于提高测量精度和信号噪声比.
主要成果:
- 模拟研究表明,SLIM设计可以大幅减少所需的样本大小.
- SLIM 设计最大限度地减少了学科间的变化,并提高了学科内部估计的精度.
- SLIM非常适合用于评估血生物标志物的早期,短期试验.
结论:
- 对于特定的ADRD试验应用,SLIM设计为传统平行组设计提供了一个统计学上强大且具有成本效益的替代方案.
- 它对血生物标志物特别有效,但不适用于受实践或安慰剂影响的结果.
- 在早期临床试验中,SLIM可以显著降低招聘负担.
更多相关视频
13:54A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
Published on: August 18, 2023
5.8K
07:35Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
7.9K
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
404
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
404
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
205
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
205